24/7 Market News Snapshot 02 June, 2025 – Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP)

June 2, 2025

DENVER, Colo., 02 June, 2025 (www.247marketnews.com) – (Nasdaq:RAPP) are discussed in this article.
Rapport Therapeutics, Inc. (Nasdaq:RAPP), a clinical-stage biotechnology company dedicated to developing small molecule precision medicines for neurological and psychiatric disorders, is experiencing notable market activity with its stock currently trading at $9.425, reflecting a substantial 13.97% rise from a previous close of $8.27. Following a strong opening at $8.39, the trading volume has reached 574.24K, highlighting robust investor engagement. As the price holds above critical support levels, surpassing the $9.50 threshold may invite further gains, while a pullback toward the $8.50 range could provide attractive buying opportunities.

In conjunction with its stock performance, Rapport Therapeutics has announced its inaugural Investor and Analyst Day, scheduled for June 2, 2025. This important event will feature insights from the executive team about the company’s strategic priorities and progress in its clinical pipeline, specifically focusing on the Phase 2a trial of RAP-219 aimed at treating focal epilepsy. A highlighted segment of the event will include a fireside chat with Dr. Jacqueline French, an esteemed key opinion leader in neurology, who will discuss the trial design and the significant unmet needs in this area.

“Our Phase 2a trial for RAP-219 is fully enrolled, and we expect to share topline results in September 2025,” stated Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics. The Investor and Analyst Day will explore several key topics, including baseline patient characteristics, treatment-emergent adverse events, and upcoming milestones in the development of RAP-219, which is poised to enter trials for bipolar mania later this year.

With $285.4 million in cash and investments reported as of March 31, 2025, Rapport Therapeutics is strategically positioned to sustain its operations through the end of 2026, significantly advancing its mission to revolutionize treatment options for patients facing refractory conditions.

Related news for (RAPP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.